Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome01:23

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Home blood pressure trajectories during 3 months of continuous positive airway pressure therapy in sleepy vs. non-sleepy patients.

Annals of the American Thoracic Society·2026
Same author

An overview of longitudinal data analyses in sleep research.

Sleep medicine·2025
Same author

Home Blood Pressure Trajectories during 6 Months of Continuous Positive Airway Pressure Therapy: Results from the eMEUSE-SANTE and SLEEPCONNECT Clinical Trials.

Annals of the American Thoracic Society·2025
Same author

Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study.

Sleep medicine·2025
Same author

Efficacy and safety of pitolisant in residual excessive daytime sleepiness for patients with obstructive sleep apnea adhering to continuous positive airway pressure therapy in the HAROSA studies: An individual patient meta-analytical approach.

Sleep medicine·2025
Same author

Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study.

Journal of sleep research·2024

Related Experiment Video

Updated: May 25, 2026

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
09:44

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

The Bowel Function Index: a new validated scale for assessing opioid-induced constipation.

Philippe Ducrotté1, Christian Caussé

  • 1HepatoGastroEnterology Department CHU, Rouen, France.

Current Medical Research and Opinion
|January 13, 2012
PubMed
Summary

The Bowel Function Index (BFI) is a validated tool for assessing opioid-induced constipation (OIC). This physician-administered scale accurately captures patient perception, aiding treatment compliance.

Related Experiment Videos

Last Updated: May 25, 2026

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation
09:44

Functional Assessment of Intestinal Motility and Gut Wall Inflammation in Rodents: Analyses in a Standardized Model of Intestinal Manipulation

Published on: September 11, 2012

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Clinical Assessment

Background:

  • Opioid-induced constipation (OIC) management is challenging due to discrepancies between clinical measures and patient perception.
  • Patient-reported outcomes are crucial for OIC management to improve treatment adherence.

Purpose of the Study:

  • To validate the Bowel Function Index (BFI) as a reliable and clinically valid patient-assessment scale for OIC.
  • To establish a clinically relevant change in BFI score for OIC.

Main Methods:

  • The Bowel Function Index (BFI), a three-item physician-administered scale, was developed and validated for OIC.
  • Validation involved extensive analysis of major clinical trials, an open-label study, and a pharmaco-epidemiological study.

Main Results:

  • The BFI demonstrated reliability, stability, clinical validity, and responsiveness to change in OIC patients.
  • A 12-point change in BFI score signifies a clinically relevant improvement in constipation.
  • Physician administration minimizes comprehension issues and captures patient perspective effectively.

Conclusions:

  • The Bowel Function Index (BFI) is a valuable tool for assessing OIC in clinical trials.
  • The BFI is suitable for routine clinical practice to evaluate opioid-induced constipation.